ESALF
Eisai Co., Ltd.
Set alert
- YTD
- +0.81%
- 1 year
- +9.02%
- Open
- 31.50
- Prev close
- 29.97
- Mkt cap
- 8.46B
- Vol
- 150
- Avg vol
- 295
- EPS
- 0.91
- P/E
- 32.93
More statistics
- Low
- 31.50
- High
- 31.50
- Earnings
- Nov 10, 2026
News
2 months ago seekingalpha.com
Eisai Co., Ltd. (ESAIY) Q1 2027 Earnings Call Transcript
Eisai Co., Ltd. (ESAIY) Q1 2027 Earnings Call Transcript
3 months ago reuters.com
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug
The U.S. FDA on Monday approved an at-home starting dose of Eisai's and Biogen's Alzheimer's drug, allowing some patients to begin therapy with injections administered by themselves or a caregiver.
5 months ago seekingalpha.com
Eisai Co., Ltd. (ESAIY) Analyst/Investor Day Transcript
Eisai Co., Ltd. (ESAIY) Analyst/Investor Day Transcript
5 months ago prnewswire.com
BioArctic Interim Report for the period January - March 2026
STOCKHOLM, May 20, 2026 /PRNewswire/ -- Strong financial performance with commercial milestone reached Events during the first quarter 2026 Leqembi® Iqlik™ (subcutaneous formulation) was granted…
5 months ago seekingalpha.com
Eisai Co., Ltd. (ESAIY) Q4 2026 Earnings Call Transcript
Eisai Co., Ltd. (ESAIY) Q4 2026 Earnings Call Transcript
6 months ago reuters.com
Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage study
Merck and Eisai's experimental combination treatments for a type of kidney cancer failed to meet the main goals of a late-stage study, the companies said on Tuesday.
6 months ago marketwatch.com
These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.
A scientific report has raised questions about how much Leqimbi and Kisunla — the “breakthrough” Alzheimer's drugs that have hit the market in the last few years — really help slow the disease.
6 months ago prnewswire.com
Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer's Disease at the 78th American Academy of Neurology's Annual Meeting
NUTLEY, N.J., April 9, 2026 /PRNewswire/ -- Eisai Inc. announced today the company will present the latest findings on lecanemab (generic name, brand name: LEQEMBI®), Eisai's anti-amyloid beta (Aβ)…
7 months ago prnewswire.com
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
The Marketing Authorisation Application (MAA) has been validated and accepted for full approval consideration with a standard review timeline Additional filings are planned for the U.K., Canada and…
8 months ago prnewswire.com
BioArctic Interim Report for the period October - December 2025
STOCKHOLM, Feb. 18, 2026 /PRNewswire/ -- A transformative year with record financial results Events during the fourth quarter 2025 Leqembi® Iqlik™ was launched for weekly maintenance dosing and Eisai…
8 months ago seekingalpha.com
Eisai Co., Ltd. (ESAIY) Q3 2026 Earnings Call Transcript
Eisai Co., Ltd. (ESAIY) Q3 2026 Earnings Call Transcript
9 months ago benzinga.com
Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle
CMS selects 15 high-cost prescription drugs for Medicare drug price negotiation program, expanding to include Part B drugs.
9 months ago businesswire.com
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
NEW YORK & TOKYO--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB, Corporate Headquarters: New York, NY, CEO: David Hung, M.D., “Nuvation Bio”), a global oncology company focused on tackling some of…
9 months ago businesswire.com
EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron's partner EA Pharma Co., Ltd. announces today the initiation of its Phase III clinical trial with evenamide in Japan.
10 months ago seekingalpha.com
Eisai Co., Ltd. (ESAIY) Discusses Value Creation Initiatives, ESG, and Dementia Area Contributions Transcript
Eisai Co., Ltd. (ESAIY) Discusses Value Creation Initiatives, ESG, and Dementia Area Contributions Transcript
11 months ago globenewswire.com
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025
Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer's disease by up to 8.3 years in low-amyloid group who started…
11 months ago prnewswire.com
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025
TOKYO and CAMBRIDGE, Mass., Dec. 3, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,…
11 months ago prnewswire.com
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
Etalanetug demonstrated reduction of eMTBR-tau243, a novel CSF and plasma biomarker that specifically reflects tau tangle pathology, in Phase I b /II study TOKYO , Dec. 1, 2025 /PRNewswire/ -- Eisai…
11 months ago globenewswire.com
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer's Disease in Japan
If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the initiation of treatment for this progressive, relentless disease If approved,…
11 months ago globenewswire.com
Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this…
11 months ago seekingalpha.com
Eisai Co., Ltd. (ESAIY) Q2 2026 Earnings Call Transcript
Eisai Co., Ltd. (OTCPK:ESAIY) Q2 2026 Earnings Call November 5, 2025 1:30 AM EST Company Participants Haruo Naito - CEO, Representative Corporate Officer & Director Hideki Toyosaki Terushige Iike -…